What Biaxin Treats: Main Uses and Benefits

Biaxin is the brand name for the antibiotic clarithromycin that is commonly applied in addressing conditions caused by susceptible bacteria. This medication is used across domains where additional symptomatic support is needed for conditions involving acute or disruptive episodes.

The medication helps address symptom clusters that may become intense or disruptive in various common areas, providing support that helps ease the overall symptom burden. It is relevant for easing symptoms linked to respiratory tract infections, such as acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, and acute maxillary sinusitis; uncomplicated bacterial skin and skin structure infections; and otolaryngological issues, including acute otitis media. Furthermore, clarithromycin may be part of symptomatic management for H. pylori associated conditions, assisting with maintaining functional stability during symptomatic phases.

“It contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Supports management of Symptoms that Interfere with Daily Functioning

Regulatory References

1. NIH DailyMed drug label for Clarithromycin

Biaxin (clarithromycin) eligibility is strictly defined by regulatory documents, categorizing populations based on contraindications, age, organ function, and reproductive status.

Contraindicated Populations

Clarithromycin is contraindicated for patients with known hypersensitivity to any macrolide antibacterial drug, a history of clarithromycin-associated cholestatic jaundice, or pre-existing QT prolongation or ventricular cardiac arrhythmia. It is also contraindicated for patients with severe hepatic failure in combination with renal impairment. The medicine must not be used concomitantly with drugs such as Lovastatin, Simvastatin, Pimozide, and Cisapride.

Restricted Use and Age Eligibility

Use is not recommended in pregnant women unless no alternative therapy is appropriate, and breastfeeding requires discontinuation of nursing. Safety and efficacy have not been established for infants younger than 6 months of age. Patients with severe renal impairment (CLcr < 30 mL/min) and patients with Myasthenia Gravis require caution and specific consideration upon administration.

Interactions with other medicines and products

Biaxin (clarithromycin) has several officially documented interactions that define specific constraints for co-administration, as mandated by regulatory authorities. The primary mechanistic basis for many interactions is the documented inhibition of the CYP3A4 enzyme system and the P-glycoprotein (P-gp) transporter. This inhibition can significantly increase the systemic exposure of co-administered drugs, which is the regulatory concern for many combinations.

---

Contraindicated Combinations

Regulatory labels strictly prohibit co-administration with certain medications due to the risk of severe adverse outcomes, which are classified as contraindications:

• Cardiotoxic Agents: Combination with astemizole, cisapride, pimozide, or terfenadine is prohibited due to the risk of QT interval prolongation and severe arrhythmias.
• Ergot Alkaloids: Co-administration with ergotamine and dihydroergotamine is forbidden due to the risk of acute ergot toxicity.
• Select Statins: The combination with Lovastatin and Simvastatin is prohibited because the resulting markedly increased plasma concentration carries a high risk of rhabdomyolysis.
• Other Prohibited Drugs: Lurasidone, Oral Midazolam, and Lomitapide are also strictly contraindicated.

---

Administration and Conditional Constraints

Official regulatory information specifies certain conditional rules for interactions:

• The interaction with Colchicine is explicitly a contraindication only when the patient has co-existing renal or hepatic impairment.
• Co-administration with Zidovudine requires the medicines to be separated by at least 2 hours.
• The extended-release tablets are required to be taken with food to ensure adequate systemic absorption.

Targeting the Bacterial Protein Factory (Molecular Blockade)

Clarithromycin's primary mechanism is the highly specific inhibition of bacterial protein synthesis. The molecule binds to the 23S ribosomal RNA (rRNA) within the bacterial 50S ribosomal subunit, acting as a physical plug to obstruct the nascent peptide exit tunnel. This prevents the assembly and elongation of essential bacterial proteins, resulting in an anti-proliferative state that limits the pathogen's capacity for growth and reproduction.

---

Enhanced Mechanistic Reinforcement

The overall mechanism is reinforced by the body's conversion of the parent drug into the active metabolite, 14-hydroxyclarithromycin. This metabolite also binds to the exact same 50S ribosomal subunit target, contributing to the total inhibition of the protein synthesis pathway. This concurrent action supports the sustained ribosomal blockade, which is linked to the physiological state of limited bacterial growth.

---

Constraints on Mechanistic Efficacy

The effectiveness of this mechanism is constrained by bacterial countermeasures, specifically structural changes to the target or active drug expulsion. Mechanisms like the methylation of the 23S rRNA prevent the drug from binding, while efflux pumps actively remove the drug from the cell. In these cases, the ribosomal inhibition is ineffective, resulting in the mechanistic consequence of unconstrained bacterial protein synthesis.

The administration of Biaxin (clarithromycin) is governed by specific instructions to ensure standardized systemic delivery. The primary route is Oral, provided in Immediate-Release (IR) tablets, Extended-Release (ER) tablets, and an oral suspension. The Intravenous (I.V.) route is also approved, but is typically restricted to initial treatment for severe infections, with a requirement to transition to oral therapy when feasible.

Usage patterns are defined by the formulation. Standard IR tablets are generally taken twice daily (every 12 hours), while the ER tablets are taken once daily at a 1000 mg dose. An important administration constraint is the requirement that the ER tablet must be taken with food to optimize absorption, whereas the IR tablets and suspension can be taken irrespective of meals. Procedurally, the ER tablet must be swallowed whole and must not be crushed, chewed, or broken, as this would compromise the time-release mechanism.

Treatment courses typically range from 7 to 14 days for acute infections. Specific patient populations require dosage modification: individuals with severe renal impairment (creatinine clearance < 30 mL/min) must have their dose reduced by 50% and their duration limited. If a dose is missed, it should be taken when remembered, but two doses should never be taken together to compensate for the skipped dose.

Research Evidence / Overview of Studies for Biaxin

Evidence for Acute Respiratory and Skin Infections

Research exploring the use of clarithromycin (Biaxin) for acute infections, such as community-acquired pneumonia and acute exacerbation of chronic bronchitis, mainly relies on short-term Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and were designed to include clarithromycin and other standard antibiotics as comparator treatments. Researchers primarily measured outcomes related to systemic or functional imbalance, such as changes in physical discomfort measurements, and monitored the measurement of the bacteria's disappearance, which is known as bacteriological eradication.

Evidence for Helicobacter pylori Eradication

Clarithromycin was studied extensively for its role in the complex combination therapies used in the research examining the H. pylori bacteria, which is often linked to stomach ulcers. Randomized Controlled Trials (RCTs) and systematic reviews were the main study types used. The research examined different combination regimens, typically for a short-term course of 7 to 14 days. The sole focus of the outcomes measured was the eradication rate of the H. pylori bacteria, which was confirmed several weeks after treatment completion.

Studies conducted in regions with low rates of clarithromycin resistance reported measurements of eradication that were highly consistent. Conversely, research describes patterns where local bacterial resistance was associated with a lower measured outcome.

Long-Term Studies and Extended Follow-up

Most clinical trials focused on short-term symptom changes following the acute infection. However, some large-scale, long-term research tracked a population of patients with pre-existing coronary heart disease. This specific long-term research reported that an association with a measured increase in all-cause mortality over the subsequent years was observed in participants who had received clarithromycin, compared to those receiving a placebo. Subsequent observational research aimed to verify this pattern, but the findings were mixed.

What Research Gaps and Uncertainties Exist

A critical limitation across all indications is the growing prevalence of bacterial resistance to macrolide antibiotics. This factor introduces complexity into the evidence base, which relies on continuous monitoring. Furthermore, long-term effects are not fully established across the entire patient population, particularly concerning the potential late-term mortality pattern observed in specific cardiac cohorts. Follow-up durations were limited in most initial clinical trials, and data for certain high-risk groups remain insufficient.

Key Studies & References

1. Clarithromycin tablets, film coated, extended release (DailyMed Drug Label)
2. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

Common questions about Biaxin (FAQ)

Q: What kind of infections is Biaxin typically used for?

According to official product information, clarithromycin is indicated for treating infections caused by susceptible organisms. This includes upper and lower respiratory tract infections like pharyngitis, acute sinusitis, and bronchitis, as well as skin infections. It is also used as part of combination therapies for treating the H. pylori bacteria, which is associated with duodenal ulcers.

---

Q: Is Biaxin safe to take if I have liver problems?

Official warnings indicate that liver issues, including elevated liver enzymes and hepatitis, have been reported with clarithromycin use. Although these effects are often reversible, severe cases and fatal hepatic failure have occurred. Use requires caution for patients with existing liver issues, as these instances are generally reported in connection with serious underlying conditions.

---

Q: Can people with kidney issues take Biaxin?

Regulatory documents indicate that dosage modification is noted in the product label for individuals who have severe renal impairment, meaning their kidney function is significantly reduced. The medicine is also contraindicated (should not be used) in patients who have a combination of severe hepatic failure and kidney impairment.

---

Q: Is Biaxin safe for children to take?

Clarithromycin is prescribed for pediatric patients for certain infections and is available in formulations like an oral suspension for easier use. However, the safety and effectiveness of this medicine have not been established in infants younger than 6 months of age.

---

Q: What foods should be avoided when taking Biaxin?

Regulatory labeling specifies that co-administration with grapefruit juice is generally not recommended while taking clarithromycin. Studies indicate that grapefruit juice may increase the concentration of the medicine in the blood, which could potentially raise the risk of experiencing side effects.

---

Q: Is it okay to take Biaxin if I also take a statin drug for cholesterol?

Regulatory labeling strictly prohibits the co-administration of clarithromycin with the statin drugs lovastatin and simvastatin due to a high risk of severe muscle toxicity (rhabdomyolysis). Regulatory warnings indicate that use with other statins warrants careful consideration and potential dose modification.

---

Q: What does 'macrolide antibiotic' mean in simple terms?

Clarithromycin belongs to the macrolide class of antibiotics. This classification refers to the drug's specific mechanism of action, where it binds to a component (the 50S ribosomal subunit) inside the bacteria. This action prevents the production of proteins essential for bacterial growth, thereby stopping the infection's progression.

---

Q: Do studies support the long-term use of Biaxin for certain conditions?

Most clinical trials focus on short-term use for acute infections. However, official safety communications reference one large, long-term study conducted in patients with pre-existing coronary heart disease (CHD). This research reported an association with an increased risk of death (all-cause mortality) that was observed one year or more after the initial 2-week course of clarithromycin.

---

Q: What information is publicly available about how Biaxin is absorbed by the body?

Official documents contain pharmacokinetic information, which describes how the medicine is processed. It is described that clarithromycin is rapidly absorbed after oral administration and quickly converted by the body into its primary active metabolite. This active form, 14-hydroxyclarithromycin, then contributes to the drug's overall effect against bacteria.

---

Q: Why might a patient switch from Biaxin to a different antibiotic?

Regulatory information indicates a switch may be necessary due to several factors. These include the emergence of bacterial resistance to macrolide antibiotics, which renders the drug ineffective, or the onset of severe adverse reactions. The necessity of taking a contraindicated interacting medication is also a reason for a required change in treatment.

---

Q: What are the current research findings on Biaxin's use in combination with other drugs?

Clarithromycin is an established component of multi-drug regimens supported by research. Notably, it is used for the eradication of H. pylori bacteria associated with duodenal ulcers. It is also an indicated treatment for the prevention and treatment of Mycobacterium avium Complex (MAC) infections.

---

Q: What research studies are often cited regarding the benefits of Biaxin?

Research studies cited in official documents describe the benefits of clarithromycin using specific measurements. These measurements typically include the clinical cure rates, which refers to the resolution of symptoms, and bacteriological eradication rates, which confirms the disappearance of the target bacteria following treatment.

---

Q: Is it common to feel tired while taking Biaxin?

While fatigue or unusual tiredness is not listed among the most commonly reported side effects, it is a symptom that has been reported in regulatory summaries. If unusual tiredness or weakness is experienced, particularly alongside other concerning symptoms like nausea or dark urine, this is information typically reported to a healthcare provider.

---

Q: What are the considerations for older adults taking Biaxin?

Regulatory documents note that older adults may be more susceptible to the drug's effects on the QT interval, a measure of heart function. Since kidney function may decline with age, caution is noted, and dosage modification for severe renal impairment is a consideration noted in the product label.

---

Q: Does Biaxin interact with common pain relievers like Tylenol (acetaminophen)?

Official drug interaction lists do not typically list acetaminophen (Tylenol) as a major or moderate known drug-drug interaction with clarithromycin.

---

Q: Are there any specific supplements or vitamins that interact with Biaxin?

There is not enough official information to state that complementary or herbal remedies are safe to take with clarithromycin. Regulatory bodies note that discussion of all supplements, vitamins, and herbal remedies with a healthcare provider is generally recommended.

---

Q: Does Biaxin interact with birth control pills?

Official information indicates that clarithromycin does not typically stop hormonal contraceptives from working. However, if the medicine causes severe vomiting or diarrhea, the effectiveness of oral contraceptive pills may be affected.

---

Q: Can I drink coffee while taking Biaxin?

No specific interaction with coffee or caffeine is listed in regulatory documents. However, clarithromycin is known to interact with theophylline, a related compound found in some medications, and inquiries regarding caffeine intake are typically referred to a healthcare professional.

---

Q: Does Biaxin interact with blood thinners like warfarin?

Official drug labeling states that clarithromycin can significantly increase the effects of blood thinners like warfarin. This combination carries an increased risk of bleeding. Official labeling notes that close monitoring of blood clotting measures is necessary when these medicines are used together.

---

Q: Why does the packaging say Biaxin has a Black Box Warning?

The U.S. FDA issued a safety warning regarding an observed association with an increased risk of death in patients with pre-existing coronary heart disease (CHD). This risk was identified in a long-term study one year or more after the initial treatment course. This important safety concern is documented in the official product information.

---

Q: Can I stop taking Biaxin as soon as my symptoms improve?

Official patient guidance states that the medicine should be taken for the full prescribed duration, even if symptoms begin to improve. Stopping treatment prematurely may allow the infection to return.

---

Q: Why do official documents mention Biaxin and hearing loss?

Official safety summaries note that reversible hearing disorders, including transient hearing loss, have been reported in association with clarithromycin use. This has been particularly observed when high doses of the medicine were administered.

---

Q: Does Biaxin cause sun sensitivity?

Sun sensitivity, also known as photosensitivity, is not typically listed among the common or serious adverse reactions documented in official regulatory summaries for clarithromycin.

---

Q: Is Biaxin available as a generic medicine?

Yes, the active ingredient in Biaxin, which is clarithromycin, is available in generic form. Biaxin is the brand name historically associated with the medicine.

---

Q: What should I do if I accidentally take two doses of Biaxin?

In the event of an accidental overdose, official regulatory documents state that immediate contact with a healthcare provider or a Poison Control Center is necessary. Symptoms of overdose can include stomach upset, vomiting, and diarrhea.

---

Q: Does Biaxin have a known effect on blood sugar levels?

Changes in blood sugar levels have been reported in official adverse reaction summaries. This includes both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) in association with clarithromycin use.

---

Q: Can Biaxin be used to prevent infections?

Clarithromycin is indicated for certain uses beyond active treatment, including prophylactic use. Specifically, it is indicated for the prevention of disseminated Mycobacterium avium Complex (MAC) disease in patients with advanced HIV infection.

---

Q: Are there different strengths of Biaxin available?

Yes, the clarithromycin active ingredient is available in different strengths across its various forms. This includes immediate-release tablets, extended-release tablets, and an oral suspension.

How to Store and Dispose of Biaxin (Clarithromycin)

Official labeling defines specific storage, stability, and disposal requirements for Biaxin.

Storage Conditions

Formulation	Required Conditions	Stability Constraint
Tablets / Dry Granules	Store at Controlled Room Temperature (20 C - 25 C).	Keep container tightly closed.
Reconstituted Suspension	Store at Controlled Room Temperature. Protect from freezing.	Stable for 14 days; discard unused portion thereafter.

All Biaxin formulations must be stored out of the reach of children, away from excessive heat, light, and moisture. Do not refrigerate the oral liquid.

Disposal

Unused or expired Biaxin should be disposed of by taking it to a drug take-back program if available. If not, follow regulatory guidance to mix it with an unappealing substance, place it in a sealed bag, and discard it in the household trash. Do not flush the medication down the toilet or pour it into a drain.